| Quarterly Financials | Jun 2016 | Sept 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sept 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 |
Revenue  | 412 | 525 | 519 | 483 | 486 | 545 | 489 | 565 | 542 | 599 | 531 | 637 | 555 | 714 | 732 | 841 | 981 | 1,144 | 1,295 | 1,417 | 1,284 | 1,206 | 1,034 | 1,426 | 1,541 | 1,577 | 1,546 | 1,383 | 1,185 | 1,226 | 1,197 | 1,458 | 1,197 | 1,228 | 1,425 | 1,779 |
| Expenses | 325 | 408 | 406 | 358 | 382 | 426 | 392 | 443 | 459 | 513 | 442 | 523 | 467 | 575 | 581 | 647 | 696 | 765 | 862 | 940 | 883 | 858 | 744 | 1,028 | 1,085 | 1,127 | 1,141 | 1,095 | 1,015 | 1,037 | 1,014 | 1,198 | 1,024 | 1,045 | 1,130 | 1,300 |
| EBITDA | 87 | 116 | 112 | 125 | 104 | 119 | 97 | 122 | 83 | 86 | 89 | 114 | 88 | 139 | 150 | 194 | 285 | 379 | 433 | 477 | 401 | 348 | 291 | 398 | 456 | 450 | 405 | 287 | 170 | 190 | 184 | 260 | 174 | 183 | 295 | 479 |
| Operating Profit % | 21 % | 21 % | 20 % | 24 % | 20 % | 21 % | 18 % | 21 % | 15 % | 13 % | 17 % | 18 % | 15 % | 19 % | 20 % | 23 % | 29 % | 33 % | 33 % | 33 % | 31 % | 29 % | 28 % | 28 % | 30 % | 28 % | 26 % | 21 % | 14 % | 15 % | 15 % | 17 % | 14 % | 15 % | 20 % | 24 % |
| Depreciation | 25 | 26 | 27 | 28 | 30 | 30 | 31 | 35 | 38 | 40 | 43 | 44 | 46 | 48 | 48 | 46 | 49 | 51 | 52 | 54 | 59 | 63 | 64 | 66 | 71 | 82 | 84 | 87 | 91 | 93 | 98 | 102 | 106 | 108 | 106 | 110 |
| Interest | 28 | 25 | 31 | 17 | 19 | 20 | 18 | 23 | 22 | 25 | 24 | 18 | 23 | 26 | 21 | 21 | 15 | 14 | 17 | 22 | 27 | 22 | 23 | 31 | 29 | 40 | 43 | 53 | 39 | 42 | 51 | 51 | 49 | 53 | 58 | 56 |
| Profit Before Tax | 35 | 66 | 54 | 81 | 55 | 70 | 49 | 64 | 23 | 22 | 23 | 53 | 19 | 66 | 82 | 127 | 222 | 314 | 364 | 401 | 316 | 263 | 204 | 302 | 356 | 328 | 278 | 147 | 41 | 54 | 35 | 107 | 19 | 23 | 131 | 312 |
| Tax | 9 | 18 | 9 | 9 | 16 | 21 | 14 | 19 | 6 | 6 | 5 | 9 | 4 | 9 | 8 | 17 | 50 | 72 | 91 | 104 | 74 | 59 | 49 | 70 | 104 | 95 | 75 | 42 | 14 | 17 | 11 | 32 | 6 | 3 | 38 | 80 |
| Net Profit | 26 | 48 | 45 | 71 | 39 | 49 | 35 | 45 | 17 | 16 | 18 | 43 | 15 | 57 | 74 | 110 | 172 | 242 | 273 | 297 | 242 | 204 | 155 | 232 | 252 | 233 | 203 | 105 | 27 | 37 | 23 | 75 | 13 | 20 | 93 | 233 |
| EPS in ₹ | 3.73 | 5.18 | 4.50 | 6.75 | 3.68 | 4.61 | 3.29 | 4.26 | 1.56 | 1.53 | 1.67 | 4.07 | 1.42 | 1.06 | 1.38 | 2.06 | 3.21 | 4.53 | 5.09 | 5.53 | 4.50 | 3.76 | 2.87 | 4.29 | 4.68 | 4.33 | 3.78 | 1.90 | 0.46 | 0.69 | 0.43 | 1.40 | 0.23 | 0.37 | 1.71 | 4.34 |
Laurus Labs
657.10
-7.25
(-1.09%)
Market Cap
35,434.28 Cr
EPS
6.65
PE Ratio
111.87
Dividend Yield
0.18 %
Industry
Healthcare52 Week High
683.00
52 Week Low
414.00
PB Ratio
8.00
Debt to Equity
0.62
Sector
Pharmaceuticals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from11 analysts
Company News
View All News
Laurus Labs experienced a substantial increase in exports in May 2025, with a growth of 104% compared to May 2024. This represents more than doubling of their export figures year-over-year.
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,643.80 | #1 3,94,402.68 | 34.46 | #1 49,887.20 | 12.06 | #1 9,648 | -18.99 | 36.89 | |
6,531.50 | 1,73,390.80 | 79.22 | 8,184.00 | 0.89 | 1,600 | 23.05 | 52.65 | |
1,492.00 | 1,20,496.15 | 22.95 | 26,520.70 | 14.17 | 4,155 | 30.28 | 50.44 | |
1,323.60 | 1,10,448.51 | 19.37 | 28,905.40 | 12.36 | 5,578 | 21.14 | 61.31 | |
3,187.50 | 1,07,879.48 | 56.64 | 10,785.70 | 11.59 | 1,656 | 10.91 | 51.94 | |
953.90 | 95,984.66 | 20.64 | 19,831.50 | 13.82 | 3,831 | -0.19 | 60.33 | |
2,313.90 | 95,466.55 | 48.91 | 10,615.60 | 19.57 | 1,942 | -10.91 | 40.24 | |
1,934.00 | 88,295.02 | 27.19 | 20,141.50 | #1 19.94 | 1,936 | #1 112.49 | 43.06 | |
31,745.00 | 67,455.91 | 47.34 | 6,097.20 | 10.80 | 1,201 | 27.83 | 58.17 | |
1,091.60 | 63,400.31 | #1 18.61 | 29,559.20 | 17.55 | 3,169 | -0.50 | 35.01 |
Automatic Screeners on ScanX
Forecast
Actual
Growth Rate
Revenue Growth
11.09 %
Net Income Growth
110.70 %
Cash Flow Change
-9.62 %
ROE
88.26 %
ROCE
51.95 %
EBITDA Margin (Avg.)
26.61 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 1,894 | 2,224 | 2,653 | 3,017 | 3,331 | 3,750 | 5,751 | 6,968 | 7,660 | 8,387 | 9,336 |
| Fixed Assets | 801 | 1,021 | 1,230 | 1,481 | 1,629 | 1,726 | 2,171 | 2,653 | 3,409 | 3,890 | 4,123 |
| Current Assets | 865 | 1,003 | 1,140 | 1,248 | 1,463 | 1,812 | 3,075 | 3,345 | 3,462 | 3,835 | 4,332 |
| Capital Work in Progress | 110 | 70 | 143 | 163 | 110 | 67 | 362 | 813 | 551 | 423 | 458 |
| Investments | 0 | 7 | 3 | 3 | 3 | 3 | 3 | 31 | 50 | 124 | 233 |
| Other Assets | 983 | 1,126 | 1,277 | 1,369 | 1,589 | 1,953 | 3,215 | 3,472 | 3,651 | 3,950 | 4,521 |
| Total Liabilities | 1,894 | 2,224 | 2,653 | 3,017 | 3,331 | 3,750 | 5,751 | 6,968 | 7,660 | 8,387 | 9,336 |
| Current Liabilities | 805 | 884 | 1,121 | 1,307 | 1,424 | 1,692 | 2,457 | 2,681 | 2,432 | 3,112 | 3,540 |
| Non Current Liabilities | 365 | 483 | 202 | 227 | 349 | 288 | 693 | 928 | 1,180 | 1,159 | 1,193 |
| Total Equity | 724 | 857 | 1,330 | 1,483 | 1,558 | 1,770 | 2,601 | 3,359 | 4,049 | 4,116 | 4,603 |
| Reserve & Surplus | 642 | 774 | 1,225 | 1,371 | 1,447 | 1,658 | 2,490 | 3,244 | 3,930 | 4,003 | 4,365 |
| Share Capital | 82 | 82 | 106 | 106 | 106 | 107 | 107 | 108 | 108 | 108 | 108 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 24 | -27 | -10 | 1 | 0 | -1 | 47 | 27 | -30 | 93 | -39 |
| Investing Activities | -397 | -312 | -289 | -384 | -253 | -221 | -941 | -915 | -997 | -822 | -680 |
| Operating Activities | -65 | 182 | 332 | 343 | 298 | 347 | 733 | 911 | 994 | 666 | 602 |
| Financing Activities | 486 | 103 | -54 | 42 | -45 | -128 | 255 | 30 | -27 | 250 | 39 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 |
| Promoter | 27.45 % | 27.30 % | 27.30 % | 27.27 % | 27.27 % | 27.27 % | 27.27 % | 27.20 % | 27.20 % | 27.20 % | 27.20 % | 27.19 % | 27.19 % | 27.18 % | 27.18 % | 27.62 % | 27.62 % |
| FIIs | 0.00 % | 0.04 % | 0.04 % | 0.02 % | 0.02 % | 0.02 % | 0.00 % | 0.02 % | 0.02 % | 0.00 % | 0.00 % | 0.00 % | 25.97 % | 25.67 % | 26.08 % | 25.56 % | 25.52 % |
| DIIs | 2.06 % | 2.40 % | 2.11 % | 2.77 % | 3.51 % | 4.77 % | 8.98 % | 9.51 % | 9.74 % | 10.14 % | 10.71 % | 10.77 % | 11.77 % | 13.56 % | 13.05 % | 12.74 % | 11.77 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 34.17 % | 34.18 % | 32.91 % | 32.87 % | 31.15 % | 28.42 % | 27.96 % | 28.95 % | 28.49 % | 28.26 % | 26.49 % | 25.01 % | 23.95 % | 22.68 % | 22.67 % | 22.72 % | 23.65 % |
| Others | 36.32 % | 36.07 % | 37.65 % | 37.08 % | 38.05 % | 39.53 % | 35.80 % | 34.32 % | 34.55 % | 34.39 % | 35.60 % | 37.03 % | 11.12 % | 10.91 % | 11.03 % | 11.36 % | 11.44 % |
| No of Share Holders | 2,35,836 | 2,99,257 | 3,94,053 | 4,67,419 | 4,27,465 | 4,07,186 | 3,90,695 | 4,23,931 | 4,18,615 | 4,17,977 | 4,02,640 | 3,82,880 | 3,56,830 | 3,24,059 | 3,09,063 | 2,92,214 | 2,92,905 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 1.5 | 1.5 | 1.5 | 2.5 | 2 | 2 | 2 | 0.8 | 1.2 |
| Dividend Yield (%) | 0.00 | 1.49 | 1.88 | 2.31 | 0.69 | 0.34 | 0.67 | 0.51 | 0.13 | 0.18 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 26 Jun 2025 |  Annual General Meeting | NA | 26 Jun 2025 | 606.00 | 664.35 |
| 09 May 2025 |  Dividend | ₹ 0.80 /share | 09 May 2025 | 650.45 | 586.00 |
| 24 Apr 2025 |  Quarterly Result Announcement | NA | 24 Apr 2025 | 564.25 | 650.45 |
| 24 Jan 2025 | Quarterly Result Announcement | NA | 24 Jan 2025 | 611.75 | 585.15 |
| 06 Nov 2024 | Dividend | ₹ 0.40 /share | 06 Nov 2024 | 449.35 | 489.25 |
| 24 Oct 2024 | Quarterly Result Announcement | NA | 24 Oct 2024 | 480.30 | 449.35 |
| 11 Jul 2024 | Annual General Meeting | NA | 11 Jul 2024 | 434.40 | 472.50 |
| 08 May 2024 | Dividend | ₹ 0.40 /share | 08 May 2024 | 434.40 | 429.45 |
| 02 Nov 2023 | Dividend | ₹ 0.40 /share | 02 Nov 2023 | 396.40 | 358.90 |
| 10 May 2023 | Dividend | ₹ 1.20 /share | 10 May 2023 | 300.05 | 334.30 |
| 04 Nov 2022 | Dividend | ₹ 0.80 /share | 03 Nov 2022 | 526.20 | 477.75 |
| 11 May 2022 | Dividend | ₹ 1.20 /share | 10 May 2022 | 578.80 | 525.10 |
| 18 Nov 2021 | Dividend | ₹ 0.80 /share | 17 Nov 2021 | 574.90 | 484.00 |
| 12 May 2021 | Dividend | ₹ 0.80 /share | 11 May 2021 | 474.45 | 491.75 |
| 09 Feb 2021 | Dividend | ₹ 0.40 /share | 08 Feb 2021 | 366.20 | 356.95 |
Announcements
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
6 days ago
6 days agoAnnouncement under Regulation 30 (LODR)-Allotment of ESOP / ESPS9 days ago
9 days agoAppointment Of Mr. Jyothi Basu Abbibeni As Executive Vice President - Chemical R&DJun 05, 2025
Jun 05, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 04, 2025
Jun 04, 2025Business Responsibility and Sustainability Reporting (BRSR)Jun 03, 2025
Jun 03, 2025Reg. 34 (1) Annual Report.Jun 03, 2025
Jun 03, 2025Notice Of The 20Th Annual General Meeting For The Financial Year 2024-25Jun 03, 2025
Jun 03, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSMay 30, 2025
May 30, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 30, 2025
May 30, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 22, 2025
May 22, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 19, 2025
May 19, 2025Board Meeting Outcome for Convening Of 20Th Annual General Meeting (AGM) Of The Company On Thursday June 26 2025 Through Video Conferencing/Other Audio Visual MeansMay 15, 2025
May 15, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 09, 2025
May 09, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptApr 28, 2025
Apr 28, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationApr 25, 2025
Apr 25, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeApr 24, 2025
Apr 24, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 24, 2025
Apr 24, 2025Announcement under Regulation 30 (LODR)-Investor PresentationApr 24, 2025
Apr 24, 2025Corporate Action-Board approves DividendApr 24, 2025
Apr 24, 2025Board Meeting Outcome for Board Meeting Outcome - 24.04.2025Apr 24, 2025
Apr 24, 2025Results - Year Ended March 31 2025Apr 24, 2025
Apr 24, 2025Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Apr 15, 2025
Apr 15, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 10, 2025
Apr 10, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationApr 10, 2025
Apr 10, 2025Board Meeting Intimation for Consideration Of Audited Financial Results For The Quarter And Year Ended March 31 2025 And Payment Of 2Nd Interim Dividend For FY 2024-25Apr 10, 2025
Apr 10, 2025Corrigendum To Intimation Of Grant Of Stock Options To The Eligible Employees Dated 28.03.2025Mar 28, 2025
Mar 28, 2025Announcement under Regulation 30 (LODR)-AcquisitionMar 28, 2025
Mar 28, 2025Intimation Of Re-Appointment Of Executive Directors Of The Company Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015.Mar 28, 2025
Mar 28, 2025Intimation Of Grant Of Stock Options To The Eligible EmployeesMar 28, 2025
Mar 28, 2025Closure of Trading WindowMar 27, 2025
Mar 27, 2025Announcement under Regulation 30 (LODR)-Updates on AcquisitionMar 15, 2025
Mar 15, 2025Announcement under Regulation 30 (LODR)-AcquisitionMar 06, 2025
Mar 06, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 10, 2025
Feb 10, 2025Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jan 31, 2025
Jan 31, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jan 31, 2025
Jan 31, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptJan 29, 2025
Jan 29, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJan 27, 2025
Jan 27, 2025Rumour verification - Regulation 30(11)Jan 27, 2025
Jan 27, 2025Clarification sought from Laurus Labs LtdJan 27, 2025
Jan 27, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJan 24, 2025
Jan 24, 2025Integrated Filing (Financial)Jan 24, 2025
Jan 24, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 24, 2025
Jan 24, 2025Announcement under Regulation 30 (LODR)-Investor PresentationJan 24, 2025
Jan 24, 2025Results For The Quarter Ended 31.12.2024Jan 24, 2025
Jan 24, 2025Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jan 22, 2025
Jan 22, 2025Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jan 15, 2025
Jan 15, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 10, 2025
Jan 10, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 08, 2025
Jan 08, 2025Board Meeting Intimation for Consideration Of Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2024Jan 06, 2025
Jan 06, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSDec 31, 2024
Dec 31, 2024Technical Indicators
RSI(14)
Neutral 62.55
ATR(14)
Volatile 17.90
STOCH(9,6)
Overbought 80.56
STOCH RSI(14)
Neutral 55.11
MACD(12,26)
Bullish 3.09
ADX(14)
Strong Trend 25.53
UO(9)
Bearish 58.90
ROC(12)
Uptrend And Accelerating 8.71
WillR(14)
Neutral -24.28
Mutual Fund Holdings
SBI Innovative Opportunities Fund Direct-Growth 
Invesco India Arbitrage Fund Direct-Growth 
Tata Multicap Fund Direct - Growth 
HDFC Arbitrage Fund Wholesale Direct-Growth 
Kotak Equity Arbitrage Fund Direct-Growth 
UTI Arbitrage Fund Direct-Growth 
Edelweiss Arbitrage Fund Direct-Growth 
Union Active Momentum Fund Direct-Growth 
WhiteOak Capital Mid Cap Fund Direct - Growth 
Nippon India Arbitrage Fund Direct-Growth 
Samco Active Momentum Fund Direct - Growth 
Bandhan Arbitrage Fund Direct-Growth 
Taurus Ethical Fund Direct-Growth 
Aditya Birla Sun Life Arbitrage Fund Direct-Growth 
HSBC Arbitrage Fund Direct-Growth 
LIC MF Healthcare Fund Direct - Growth 
Axis Arbitrage Fund Direct-Growth 
Franklin India Arbitrage Fund Direct-Growth 
Bajaj Finserv Arbitrage Fund Direct-Growth About Laurus Labs
Laurus Labs is a science-led, fully integrated pharmaceutical and biotechnology manufacturing company based in India. It operates in four business lines: Generics - APIs, Generics - FDFs, Synthesis, and Ingredients. The company specializes in active pharmaceutical ingredients (APIs) for anti-retrovirals, Hepatitis C, and Oncology, among other therapeutic areas. Laurus Labs has four manufacturing facilities in Visakhapatnam, Andhra Pradesh, producing APIs, ingredients, and Finished Dosage Formulations (FDFs). The company serves global pharmaceutical markets, particularly in Sub-Saharan Africa, South-East Asia, and Latin America. Laurus Labs also offers contract development and manufacturing services, and produces specialty ingredients for the nutraceutical and cosmeceutical sectors. The company has expanded its operations through acquisitions, partnerships, and investments in new facilities and capabilities.
Listing Date
19 Dec, 2016(8 Years,
31 days)
Website
Chairperson NameRavindranath Kancherla
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
